Biontech vs Neurocrine Biosciences
Biontech and Neurocrine Biosciences are similar in size: $3.24bn and $2.86bn of revenue in their latest fiscal years. Neurocrine Biosciences grew faster (21.4% against 9.0%). Neurocrine Biosciences kept more of each dollar of sales as profit: a net margin of 16.7% against -39.6%. Biontech carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | BiontechBNTX, 2025 | Neurocrine BiosciencesNBIX, 2025 |
|---|---|---|
| Revenue | $3.24bn | $2.86bn |
| Revenue growth | 9.0% | 21.4% |
| Net income | −$1.28bn | $479m |
| Operating margin | -49.0% | 21.6% |
| Net margin | -39.6% | 16.7% |
| Return on equity | -6.0% | 16.4% |
| Free cash flow | $318m | $749m |
| Cash | $9.01bn | $713m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | 0.0% | — |
| Share buybacks | — | $168m |
| Employees | — | 1,800 |
| Market value | $21.84bn | $16.93bn |
| Price vs our value range | Below our value range | Below our value range |
| Moat score | — | 61 (Moderate) |
| Insider trades, 12 months | 0 buys, 27 sales | 0 buys, 40 sales |